Out of Tragedy Comes a New Technology.

It’s not often a rancher’s wife breaks down in tears, but 6 years ago, Brandon Ames, CEO of AniCell Biotech, took an unexpected call from his mother that would launch a pivotal shift of regenerative veterinary medicine as we know it.

On the heels of having to euthanize her favorite mare a couple of months earlier, Janette Ames was now facing the same heartbreaking inevitability for her granddaughter’s gelding.  And why? Chemical founder. A lethal drug interaction between two Corticosteroid; one to treat hock inflammation and one to treat colic.  Not just $100,000 in prized show horses gone, but beloved companions, confidence builders, and exercise partners halted a once active lifestyle of the Ames family.

Ames began to ask himself all of the “why” questions. “Why is it in the 21st century we are still just treating symptoms? Why not develop technology that actually solves the problems of hock inflammation?  Over the years I had witnessed so many treatments used to address the symptoms of injuries and very few that actually solved the root cause of the issue.”

“I was aware of a new, all-natural regenerative technology being developed and showing promising results for people with orthopedic injuries and chronic wounds such as diabetic ulcers.  We had used stem cells and other regenerative treatments in horses for years, but they were invasive, time-consuming and required painful harvesting bone marrow or fat.  Then they needed to be cultured for up to three weeks before treatment could occur. This new technology simply recycled nature’s blessings by collecting the amniotic fluid during childbirth. Why not do the same thing for horses?”

Being a lifetime entrepreneur, Ames assembled a team to research the use of amniotic stem cells and components and began finding amazing results not only for the horse and owners but for the veterinarians using them. They found that these regenerative products can be used the same day as the injury and are able to be used in the field.  Cellular Biologist and AniCell team member, Dr. Moises Barcelo said: “We’re also very excited about the prospects of use as a preventative technology.”

This technology is provisionally patented for use in horses and dogs to aid in the wound management of tendons, ligaments, joints, hard-to-heal wounds and eyes. When referring to this new venture that finds him uniting with others who are on the forefront of transforming veterinary medicine Ames says, “quite simply, we are in the recycling business, collecting the miracles of regenerative products from nature’s blessings that would otherwise end up on the ground.”